Find in Library
Search millions of books, articles, and more
Indexed Open Access Databases
c-Myb Exacerbates Atherosclerosis through Regulation of Protective IgM-Producing Antibody-Secreting Cells
oleh: Eric A. Shikatani, Rickvinder Besla, Sherine Ensan, Aditi Upadhye, Nadiya Khyzha, Angela Li, Takuo Emoto, Felix Chiu, Norbert Degousee, Joshua M. Moreau, Heather M. Perry, Danya Thayaparan, Henry S. Cheng, Shaun Pacheco, David Smyth, Hossein Noyan, Caleb C.J. Zavitz, Carla M.T. Bauer, Ingo Hilgendorf, Peter Libby, Filip K. Swirski, Jennifer L. Gommerman, Jason E. Fish, Martin R. Stampfli, Myron I. Cybulsky, Barry B. Rubin, Christopher J. Paige, Timothy P. Bender, Coleen A. McNamara, Mansoor Husain, Clinton S. Robbins
Format: | Article |
---|---|
Diterbitkan: | Elsevier 2019-05-01 |
Deskripsi
Summary: Mechanisms that govern transcriptional regulation of inflammation in atherosclerosis remain largely unknown. Here, we identify the nuclear transcription factor c-Myb as an important mediator of atherosclerotic disease in mice. Atherosclerosis-prone animals fed a diet high in cholesterol exhibit increased levels of c-Myb in the bone marrow. Use of mice that either harbor a c-Myb hypomorphic allele or where c-Myb has been preferentially deleted in B cell lineages revealed that c-Myb potentiates atherosclerosis directly through its effects on B lymphocytes. Reduced c-Myb activity prevents the expansion of atherogenic B2 cells yet associates with increased numbers of IgM-producing antibody-secreting cells (IgM-ASCs) and elevated levels of atheroprotective oxidized low-density lipoprotein (OxLDL)-specific IgM antibodies. Transcriptional profiling revealed that c-Myb has a limited effect on B cell function but is integral in maintaining B cell progenitor populations in the bone marrow. Thus, targeted disruption of c-Myb beneficially modulates the complex biology of B cells in cardiovascular disease. : Shikatani et al. demonstrate that the nuclear transcription factor c-Myb exacerbates experimental atherosclerosis directly through its effects on B lymphocytes. Paradoxically, c-Myb promotes B2 cell development yet limits numbers of IgM-producing antibody-secreting cells and levels of atheroprotective OxLDL-specific IgM antibodies.